Insights
What is moving in medical weight management and longevity right now, and where your practice fits.
New, April 2026
The FDA approved orforglipron, the first non-peptide oral GLP-1, taken daily with no fasting. A pill broadens who starts treatment, which raises the value of the nutrition, monitoring and whole-body care a practice already provides around it.
Source: Healio
The bottleneck
GLP-1 results depend on protein and eating behavior, and demand for registered-dietitian counseling is outpacing supply, with the field projected to keep growing. A branded program lets your practice keep both the patient and the nutrition work while a clinician handles the prescription.
Source: Bureau of Labor Statistics
Demand, with a caveat
In a year, searches for sermorelin rose over 230% and NAD+ over 120%. But the anti-aging claims driving that demand are not yet backed by human outcome trials. Practices that offer clinician-guided, evidence-honest programs earn the trust the hype does not.
Source: Medical Daily
External research describes the medication category and the market, not any Local Healthcare program's results.